2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 3, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the efficacy and safety of disitamab vedotin (DV), developed...
Siemens Healthineers Wins Best Office Interior (Malaysia) at Asia Pacific Property Awards 2024–2025
New Kuala Lumpur office, designed with Space Matrix, sets a benchmark in workplace innovation and cultural expression. KUALA LUMPUR, Malaysia, June 3, 2025 /PRNewswire/ -- Siemens Healthineers Malaysia has been recognized for excellence in workplace design, winning Best Office Interior (Malaysia) at the Asia Pacific International Property Awards...
The Gut-Skin-Wellness Connection: How Your Microbiome Affects More Than Just Digestion
KUALA LUMPUR, Malaysia, June 3, 2025 /PRNewswire/ -- In conjunction with World Digestive Health Day, SpaceGut, Malaysia's first AI-powered at-home Gut Microbiome Test Kit, empowers individuals to improve skin health and sleep quality through personalised diet plans based on advanced gut analysis. By identifying specific bacterial species related to inflammation, metabolic function, and immune modulation, SpaceGut helps address common...
OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the...
CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant high-grade serous ovarian cancer (HGSOC) without CDH6 pre-selection PRINCETON, N.J., June 2, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated...
Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil
New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national research excellence LONDON, June 2, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the renewal of its multi-year partnership with CAPES (Coordenação de...
International Healthcare Week 2025 – Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- International Healthcare Week (IHW) 2025, Southeast Asia's premier healthcare event, will be held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (MITEC), Kuala Lumpur. Organised by Informa Markets, IHW 2025 is set to be a transformative platform that accelerates healthcare innovation, fosters regional collaboration, and...
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025...
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics. This partnership...
Dilon Technologies Partners with Australian Allografts as Exclusive Distributor for Navigator 2.0™ Gamma Localization System in Australia
NEWPORT NEWS, Va., June 2, 2025 /PRNewswire/ -- Dilon Technologies is pleased to announce the partnership of Australian Allografts as the exclusive distributor of the Navigator 2.0™ Lymphatic Mapping System in Australia, effective immediately. This strategic collaboration reflects Dilon Technologies' ongoing commitment to delivering exceptional patient care through advanced medical technology. By...
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive,...
